ChemoMetec (CHEMM.CO) Stock Analysis & AI Equity Report

Medical - Devices DKK Explore free reports

ChemoMetec (CHEMM.CO) overview

ChemoMetec (CHEMM.CO) stock analysis and AI equity research. For the latest completed financial year, 2025, ChemoMetec reported revenue of DKK 496m and operating profit of DKK 248m; the year-end share price was 584.50 DKK and market capitalisation was DKK 10,173m. ChemoMetec is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get ChemoMetec's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueDKK 673mFY 2025
Share price584.50 DKKFY 2025 year end
RevenueDKK 496mFY 2025
Operating profitDKK 248mFY 2025
Net earningsDKK 186mFY 2025
Market capitalisationDKK 10,173mFY 2025 year end

Figures updated on 2026-07-27. Data will be refreshed during report generation.

About ChemoMetec

ChemoMetec develops, manufactures, and sells analytical instruments for cell counting and cell analysis. Its NucleoCounter and XcytoMatic systems are used in biopharmaceutical production, cell and gene therapy, research, and quality control, supported by consumables and software. The company also serves related applications in agriculture and other life science workflows.

Generate the ChemoMetec report

ChemoMetec is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for ChemoMetec and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on ChemoMetec

Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.